Good morning :)
Place Order
Add to Watchlist

Alkem Laboratories Ltd

ALKEM

Alkem Laboratories Ltd

ALKEM
Health CarePharmaceuticals
MidcapWith a market cap of ₹65,275 cr, stock is ranked 152
Low RiskStock is 1.87x as volatile as Nifty
5,489.950.56% (+30.50)
5,489.950.56% (+30.50)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
MidcapWith a market cap of ₹65,275 cr, stock is ranked 152
Low RiskStock is 1.87x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
MidcapWith a market cap of ₹65,275 cr, stock is ranked 152
Low RiskStock is 1.87x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
30.766.090.73%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.536.560.52%

Forecast & Ratings

Detailed Forecast 
47%
Analysts have suggested that investors can buy this stock

from 19 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Alkem Laboratories Limited is engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products.

Investor Presentation

View older 

Nov 13, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 11.76%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 3.39% to 3.44%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 18.75%, vs industry avg of 15.27%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue5,164.555,799.546,516.597,444.898,448.589,098.2210,796.8411,815.3412,978.4213,142.78
Raw Materialssubtract2,068.322,511.132,477.742,941.333,574.893,832.304,715.774,444.474,923.4610,298.97
Power & Fuel Costsubtract66.3386.34112.64121.48130.14129.95162.96163.94162.58
Employee Costsubtract861.081,003.851,191.641,362.461,505.491,621.031,962.712,131.352,201.01
Selling & Administrative Expensessubtract879.561,014.861,175.611,288.441,412.401,224.581,722.202,163.712,163.46
Operating & Other expensessubtract196.3072.40434.62528.71248.05114.7632.591,189.321,093.07
Depreciation/Amortizationsubtract93.31101.17143.03193.18252.76274.58303.96310.42299.30312.38
Interest & Other Itemssubtract71.2445.1655.3354.6365.0658.9252.37107.36112.41109.57
Taxes & Other Itemssubtract186.8272.60295.04194.15132.72257.08198.66320.60227.36299.54
EPS62.0274.6152.7763.6194.26132.57137.6382.31150.19177.50
DPS12.7015.0013.0016.0025.0030.0034.0050.0040.0040.00
Payout ratio0.200.200.250.250.270.230.250.610.270.23

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

May 13PDF
Feb 4PDF
Nov 12PDF
Aug 6PDF
FY 2023

Annual Report Unavailable

Investor Presentation

May 19PDF
Feb 10PDF
Nov 11PDF
Aug 5PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 10PDF
FY 2025

Annual Report Pending

Investor Presentation

Nov 13PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Alkem Laboratories Ltd36.356.090.73%
Sun Pharmaceutical Industries Ltd45.356.470.75%
Cipla Ltd28.514.380.89%
Torrent Pharmaceuticals Ltd68.4516.540.84%

Price Comparison

Compare ALKEM with any stock or ETF
Compare ALKEM with any stock or ETF
ALKEM
Loading...

Shareholdings

Promoter Holdings Trend

Decreased Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 1.08%

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding55.66%14.94%4.27%9.02%16.10%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep5.64%6.03%8.49%9.11%8.69%9.02%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Alkem Laboratories Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
ICICI Prudential Multi-Asset Fund - Growth - Direct Plan

Growth
0.8897%1.14%-0.13%61/228 (-1)
Axis Midcap Fund - Growth - Direct Plan

Growth
0.7974%1.72%0.33%16/113 (+8)
SBI Large & Midcap Fund - Growth - Direct Plan

Growth
0.7418%1.65%0.43%15/85 (-3)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Alkem Laboratories Ltd

Events

Dividend Trend

No Trend In Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

ALKEM has shown inconsistent dividend trend over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.73%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹7.33 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateAug 9, 2024

Final
Final | Div/Share: ₹5.00

Dividend/Share

₹5.00

Ex DateEx Date

Aug 9, 2024

Cash Dividend

Ex DateEx DateFeb 16, 2024

Interim
Interim | Div/Share: ₹35.00

Dividend/Share

₹35.00

Ex DateEx Date

Feb 16, 2024

Cash Dividend

Ex DateEx DateAug 10, 2023

Final
Final | Div/Share: ₹10.00

Dividend/Share

₹10.00

Ex DateEx Date

Aug 10, 2023

Cash Dividend

Ex DateEx DateFeb 17, 2023

Special
Special | Div/Share: ₹25.00

Dividend/Share

₹25.00

Ex DateEx Date

Feb 17, 2023

Cash Dividend

Ex DateEx DateFeb 17, 2023

Interim
Interim | Div/Share: ₹15.00

Dividend/Share

₹15.00

Ex DateEx Date

Feb 17, 2023

News & Opinions
Corporate
Board of Alkem Laboratories approves transfer of its trade generics biz to Alkem Wellness

The Board of Directors of Alkem Laboratories at its meeting held today i.e.10 December 2024 approved the transfer of the trade generics business of the Company as a going concern, on a slump sale basis, to Alkem Wellness, a wholly owned subsidiary of the Company, incorporated in India. The transaction is proposed to be effected through a business transfer agreement and will be effective on or before 1 April 2025 or such other date as may be mutually agreed between the parties, subject to customary closing conditions.Powered by Capital Market - Live

1 day agoCapital Market - Live
Spotlight
Alkem Laboratories Ltd spurts 1.4%

Alkem Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 5721.55, up 1.4% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.22% on the day, quoting at 24184. The Sensex is at 79872.83, up 0.09%. Alkem Laboratories Ltd has dropped around 1.32% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has dropped around 0.69% in last one month and is currently quoting at 22240.2, up 1.08% on the day. The volume in the stock stood at 82592 shares today, compared to the daily average of 5.98 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 5751.2, up 1.67% on the day. Alkem Laboratories Ltd is up 24.03% in last one year as compared to a 16.91% spurt in NIFTY and a 38.53% spurt in the Nifty Pharma index.The PE of the stock is 31.19 based on TTM earnings ending September 24.Powered by Capital Market - Live

1 week agoCapital Market - Live
Earnings
Alkem Laboratories consolidated net profit rises 10.98% in the September 2024 quarter

Net profit of Alkem Laboratories rose 10.98% to Rs 688.64 crore in the quarter ended September 2024 as against Rs 620.52 crore during the previous quarter ended September 2023. Sales declined 0.74% to Rs 3414.67 crore in the quarter ended September 2024 as against Rs 3440.17 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3414.673440.17 -1 OPM %22.0521.71 - PBDT859.17779.60 10 PBT780.26705.70 11 NP688.64620.52 11 Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Spotlight
Alkem Laboratories Ltd eases for fifth straight session

Alkem Laboratories Ltd fell for a fifth straight session today. The stock is quoting at Rs 5383.3, down 2.18% on the day as on 12:59 IST on the NSE. The benchmark NIFTY is down around 0.94% on the day, quoting at 23659.1. The Sensex is at 78018.99, down 0.83%.Alkem Laboratories Ltd has eased around 13.89% in last one month.Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has eased around 7.95% in last one month and is currently quoting at 22151.6, down 1.6% on the day. The volume in the stock stood at 1.8 lakh shares today, compared to the daily average of 1.92 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 5426, down 1.11% on the day. Alkem Laboratories Ltd jumped 23.9% in last one year as compared to a 20.25% rally in NIFTY and a 40.48% spurt in the Nifty Pharma index.The PE of the stock is 31.15 based on TTM earnings ending June 24.Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Corporate
Alkem Laboratories to conduct board meeting

Alkem Laboratories will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Alkem Laboratories inks licensing agreement with Sonnet

Alkem Laboratories has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings, Inc (Sonnet) to develop, manufacture and commercialise the drug candidate 'SON-080' for the treatment of diabetic peripheral neuropathy in India. 'SON-080' is Sonnet's proprietary version of 'atexakin alfa'. It has shown encouraging data in phase 1b clinical trial. The drug candidate was demonstrated to be well-tolerated and the pain and quality of life survey results suggested a potential for rapid improvement of peripheral neuropathy symptoms and post-dosing durability, compared to placebo controls. Under the licensing agreement, Alkem will carry out the clinical development of 'SON-080' in India with support from Sonnet and enable global and India regulatory filings. Alkem has exclusive rights to develop, manufacture and commercialise the drug in India.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Alkem Labs signs licensing agreement with Sonnet BioTherapeutics

SON-080 is Sonnet's proprietary version of 'atexakin alfa'. It has shown encouraging data in phase 1b clinical trial. The drug candidate was demonstrated to be well-tolerated and the pain and quality of life survey results suggested a potential for rapid improvement of peripheral neuropathy symptoms and post-dosing durability, compared to placebo controls. Under the licensing agreement, Alkem will carry out the clinical development of 'SON-080' in India with support from Sonnet and enable global and India regulatory filings. Alkem has exclusive rights to develop, manufacture and commercialise the drug in India. According to company, 'SON-080' has undergone many years of development and the previous clinical trials have generated safety data from over 200 patients. 'SON-080' has demonstrated compelling preclinical efficacy data in both diabetic peripheral neuropathy and chemotherapy induced neuropathy, including the ability to prevent the development of neuropathy and reverse established neuropathy when assessed by nerve conduction, histological integrity and sensorimotor function measurements. Dr. Akhilesh Sharma, president & chief medical officer of Alkem said, 'We are pleased to partner with Sonnet for this programme. We believe 'SON-080' is a unique asset that has demonstrated promising disease modifying potential for diabetic peripheral neuropathy with translational studies showing nerve regeneration. There is a large prevalence of diabetic peripheral neuropathy in India, which we believe underscores the need for the drug development in this territory and potential value.' Pankaj Mohan, founder & chief executive officer of Sonnet, said, 'We are excited to partner with Alkem and look forward to advancing 'SON-080' into phase 2 clinical development. We believe that Alkem is the ideal partner with significant experience and expertise.' Alkem Laboratories is engaged in pharmaceutical business with global operations. The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company reported 90.13% jump in consolidated net profit to Rs 545.16 crore on 2.16% rise in revenue from operations to Rs 3,031.82 crore in Q1 FY25 over Q1 FY24. Shares of Alkem Laboratories slipped 3.17% to currently trade at Rs 6,090.55 on the BSE.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Alkem Laboratories Ltd rises for third consecutive session

Alkem Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 6295, up 1.4% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.06% on the day, quoting at 25182.65. The Sensex is at 82274.5, down 0.09%. Alkem Laboratories Ltd has risen around 18.26% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has risen around 8.25% in last one month and is currently quoting at 23184.4, up 0.68% on the day. The volume in the stock stood at 2.52 lakh shares today, compared to the daily average of 3.65 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 6309.05, up 1.17% on the day. Alkem Laboratories Ltd is up 72.23% in last one year as compared to a 28.41% spurt in NIFTY and a 52.01% spurt in the Nifty Pharma index.The PE of the stock is 35.16 based on TTM earnings ending June 24.Powered by Capital Market - Live

3 months agoCapital Market - Live
Spotlight
Alkem Laboratories Ltd spurts 2.93%, up for fifth straight session

Alkem Laboratories Ltd is up for a fifth straight session today. The stock is quoting at Rs 6174.95, up 2.93% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.35% on the day, quoting at 25240.45. The Sensex is at 82401.53, up 0.32%. Alkem Laboratories Ltd has gained around 16.3% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has gained around 6.75% in last one month and is currently quoting at 22878.05, up 1.61% on the day. The volume in the stock stood at 2.31 lakh shares today, compared to the daily average of 3.57 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 6198, up 2.63% on the day. Alkem Laboratories Ltd is up 69.51% in last one year as compared to a 31.09% jump in NIFTY and a 54% jump in the Nifty Pharma index.The PE of the stock is 33.97 based on TTM earnings ending June 24.Powered by Capital Market - Live

3 months agoCapital Market - Live
Spotlight
Alkem Laboratories Ltd soars 1.08%, Gains for third straight session

Alkem Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 5954.65, up 1.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.31% on the day, quoting at 25094.85. The Sensex is at 81939.19, up 0.28%. Alkem Laboratories Ltd has added around 14.47% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has added around 5.53% in last one month and is currently quoting at 22729, up 0.64% on the day. The volume in the stock stood at 1.9 lakh shares today, compared to the daily average of 3.42 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 5956.65, up 1.11% on the day. Alkem Laboratories Ltd is up 60.84% in last one year as compared to a 29.74% gain in NIFTY and a 51.27% gain in the Nifty Pharma index.The PE of the stock is 33.35 based on TTM earnings ending June 24.Powered by Capital Market - Live

3 months agoCapital Market - Live